Table 1.
Baseline characteristics of participants between rapid EGFR decline group and non-rapid EGFR decline group
| Characteristics | Overall (n=4142) |
Rapid eGFR decline (n=711) |
Non-rapid eGFR decline (n=3431) |
P value |
| Male (n (%)) | 1874 (45.2) | 351 (49.4) | 1523 (44.4) | 0.02 |
| Age (years) | 58 (52~64) | 59 (52~66) | 58 (52~64) | 0.02 |
| Married with spouse (n (%)) | 3548 (87.5) | 610 (85.8) | 2938 (85.6) | 0.91 |
| Education | ||||
| Illiterate (n (%)) | 1206 (29.1) | 191 (26.9) | 1015 (29.6) | 0.28 |
| Middle school and below (n (%)) | 1770 (41.2) | 309 (43.5) | 1398 (40.7) | |
| High school and above (n (%)) | 1229 (29.7) | 211 (29.7) | 1018 (29.7) | |
| Household per capita income (yuan) | 6461.0 | 6000.0 | 6560.0 | 0.20 |
| M (P25~P75) | (2336.7~13 487.5) | (1866.7~13 490.0) | (2450.0~13 486.7) | |
| Drink (n (%)) | 1470 (32.2) | 234 (32.9) | 1173 (34.2) | 0.51 |
| Smoke (n (%)) | 1567 (37.8) | 272 (38.3) | 1295 (37.7) | 0.80 |
| Blood urea nitrogen (mg/dL) | 15.0 (12.5~17.8) | 15.1 (12.6~18.2) | 15.0 (12.5~17.7) | 0.18 |
| Fasting glucose (mg/dL) | 102.4 (94.9~111.2) | 100.6 (93.4~109.8) | 102.4 (95.2~111.4) | 0.001 |
| Creatinine (mg/dL) | 0.75 (0.64~0.84) | 0.71 (0.60~0.84) | 0.76 (0.64~0.86) | 0.001 |
| Total cholesterol (mg/dL) | 190.6 (168.6~215.8) | 189.8 (164.7~215.3) | 190.6 (169.3~216.1) | 0.20 |
| Triglyceride (mg/dL) | 105.3 (74.3~148.7) | 101.8 (71.7~146) | 106.2 (74.3~148.7) | 0.23 |
| HDL cholesterol (mg/dL) | 49.1 (41.0~59.5) | 49.5 (41.0~59.9) | 49.1 (41.0~59.5) | 0.81 |
| hs-CRP (mg/L) | 1.0 (0.5~2.0) | 1.0 (0.6~2) | 1.0 (0.5~2.0) | 0.43 |
| GHbA1c (%) | 5.1 (4.9~5.4) | 5.1 (4.9~5.4) | 5.1 (4.9~5.4) | 0.36 |
| Uric acid (mg/dL) | 4.2 (3.5~5.0) | 4.2 (3.5~5.0) | 4.2 (3.5~5.0) | 0.83 |
| Haemoglobin (mg/dL) | 14.2 (13.1~15.5) | 14.0 (12.8~15.1) | 14.3 (13.1~15.5) | 0.001 |
| eGFR (mL/min/1.73 m2) | 95.9 (86.4~102.9) | 97.0 (88.3~106.1) | 95.6 (85.9~102.4) | 0.001 |
| eGFR group | ||||
| 60~89 mL/min/1.73 m2 (n (%)) | 1368 (33.0) | 209 (29.4) | 1158 (33.8) | |
| 90~mL/min/1.73 m2 (n (%)) | 2774 (67.0) | 502 (70.6) | 2272 (66.2) | |
| Grip strength (kg) | 29.3 (23.8~36.5) | 29.5 (24.9~36.2) | 29.3 (23.5~36.7) | 0.13 |
| Grip strength group (n (%)) | 0.01 | |||
| T1 | 1386 (33.5) | 209 (29.4) | 1177 (34.3) | |
| T2 | 1387 (33.5) | 268 (37.7) | 1199 (32.6) | |
| T3 | 1369 (33.1) | 234 (32.9) | 1135 (33.1) | |
| Height (cm) | 157.7 (152.0~163.8) | 157.9 (152.0~163.7) | 157.6 (152.0~163.9) | 0.64 |
| Weight (kg) | 58 (51.3~65.5) | 57.1 (50.8~65.1) | 58.2 (51.4~65.7) | 0.08 |
| Body mass index (kg/m2) | 23.2 (21~25.7) | 22.9 (20.8~25.4) | 23.3 (21.1~25.8) | 0.01 |
| Waist circumference (cm) | 84.4 (78.0~92.0) | 83.6 (77.0~90.2) | 84.8 (78.1~92.0) | 0.01 |
| Systolic blood pressure (mm Hg) | 127 (114~141) | 128 (114~142) | 127 (114~141) | 0.72 |
| Diastolic blood pressure (mm Hg) | 75 (67~83) | 74 (66~83) | 75 (67~83) | 0.41 |
| Mean arterial pressure (mm Hg) | 92 (83~102) | 92 (83~103) | 92 (84~102) | 0.76 |
| Depression symptom (n (%)) | 1904 (46.0) | 319 (44.9) | 1585 (46.2) | 0.52 |
| Self-report hypertension (n (%)) | 887 (21.4) | 157 (22.1) | 730 (21.3) | 0.63 |
| Self-report dyslipidaemia (n (%)) | 333 (8.0) | 58 (8.2) | 275 (8.0) | 0.90 |
| Self-report diabetes or HBG (n (%)) | 191 (4.6) | 28 (3.9) | 163 (4.8) | 0.35 |
| Self-report arthritis or rheumatism (n (%)) | 1345 (32.5) | 235 (33.1) | 1110 (32.4) | 0.71 |
| Antihypertensive therapy (n (%)) | 664 (16.0) | 119 (16.7) | 545 (19.5) | 0.57 |
| Lipid-lowering therapy (n (%)) | 187 (4.5) | 37 (5.2) | 150 (4.4) | 0.33 |
| Hypoglycaemic therapy (n (%)) | 127 (3.1) | 19 (2.7) | 108 (3.1) | 0.50 |
| Therapy for arthritis or rheumatism (n (%)) | 643 (15.5) | 116 (16.3) | 527 (15.4) | 0.52 |
| MetS (n (%)) | 1321 (31.9) | 207 (29.1) | 1114 (32.5) | 0.08 |
| MetS scores | −0.1 (−0.4~0.3) | −0.1 (−0.5~0.3) | 0 (−0.4~0.3) | 0.02 |
| MetS components (n (%)) | ||||
| Central obesity | 1726 (41.7) | 264 (37.1) | 1462 (42.6) | 0.01 |
| Elevated blood pressure | 2099 (50.7) | 368 (51.8) | 1731 (50.5) | 0.52 |
| Dyslipidaemia | 1595 (38.5) | 278 (39.1) | 1317 (38.4) | 0.72 |
| Elevated blood glucose | 2456 (59.3) | 383 (53.9) | 2073 (60.4) | <0.01 |
| Baseline non-MetS group (n (%)) | ||||
| MetS free | 2460 (59.4) | 444 (62.4) | 2016 (58.8) | |
| MetS developed | 361 (8.7) | 60 (8.4) | 301 (8.8) | |
| Baseline MetS group (n (%)) | ||||
| MetS recovery | 499 (12.0) | 64 (9.0) | 435 (12.7) | |
| MetS chronic | 822 (19.8) | 143 (20.1) | 679 (19.8) |
Data are n (%) or median (IQR).
Grip strength is divided into T1, T2 and T3 groups by one-third percentile.
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C reactive protein; MetS, metabolic syndrome.